Hypertermic Intrathoracic Chemotherapy (HITHOC) for thymoma: a narrative review on indications and results

被引:12
作者
Aprile, Vittorio [1 ]
Bacchin, Diana [1 ]
Korasidis, Stylianos [1 ]
Ricciardi, Roberta [2 ]
Petrini, Iacopo [3 ]
Ambrogi, Marcello Carlo [1 ]
Lucchi, Marco [1 ]
机构
[1] Univ Pisa, Cardiac Thorac & Vasc Dept, Thorac Surg, Pisa, Italy
[2] Univ Pisa, Dept Clin & Expt Med, Neurol Unit, Pisa, Italy
[3] Univ Hosp Pisa, Dept Crit Area & Surg, Unit Resp Med, Med & Mol Pathol, Pisa, Italy
关键词
Hypertermic intrathoracic chemotherapy (HITHOC); thymoma; intracavitary chemotherapy; hyperthermia; redo-surgery; MALIGNANT PLEURAL MESOTHELIOMA; CYTOREDUCTIVE SURGERY; INTRAPLEURAL PERFUSION; CISPLATIN; RECURRENCE; RESECTION; PHARMACOKINETICS; HYPERTHERMIA; FEASIBILITY; PLEURECTOMY;
D O I
10.21037/atm-20-6704
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: With this narrative review, we retraced the history of hypertermic intrathoracic chemotherapy (HITHOC) since the beginning, analyzing literature on operative technique, feasibility and efficacy of this treatment. Moreover, we report the fifteen-year experience of our center in this relatively new technique, for what concerns both early postoperative results and long-term oncological outcomes. Background: Thymomas are frequently misdiagnosed and recognized in advanced stage, often with pleural dissemination, especially when not associated to Myasthenia Gravis that allows an early diagnosis during the initial assessment. Moreover, the natural history of locally advanced thymoma is characterized by a high rate of pleural or pericardial relapses. Surgery has always been considered a milestone in thymoma's treatment, even in case of serous dissemination or relapses, although his role as exclusive therapy does not guarantee an acceptable local disease control. In case of disseminated disease, different multidisciplinary protocols have been experimented, from chemotherapy to radiation therapy, alone or associated to surgery, in order to increase overall and disease-free survival, but the breakthrough happened in the early 90s with the introduction of HITHOC following surgery. Combination of surgery and HITHOC resulted in less toxic than systemic chemotherapy and providing a good local disease control in patients with stage IVa thymomas or thymoma's pleural recurrences. Methods: We searched PubMed for relevant literature, up to January 2020, on hypertermic intrapleural chemotherapy for thymomas (TPR or DNT), selecting only those reporting information about HITHOC protocol used, postoperative course and oncological outcomes. Conclusions: HITHOC is a safe and feasible procedure, with a very low complication rate and negligible systemic effects of chemotherapeutic agents, effective in controlling both TPR and DNT, in particular as regards local disease-free survival.
引用
收藏
页数:12
相关论文
共 43 条
  • [1] Pleural recurrence of thymoma: surgical resection followed by hyperthermic intrathoracic perfusion chemotherapy
    Ambrogi, Marcello Carlo
    Korasidis, Stylianos
    Lucchi, Marco
    Fanucchi, Olivia
    Giarratana, Silvia
    Melfi, Franca
    Mussi, Alfredo
    Zielinski, M.
    Marulli, G.
    Stamenovic, D.
    Foroulis, C.
    Luzzi, L.
    [J]. EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2016, 49 (01) : 321 - 326
  • [2] Surgical treatment of pleural recurrence of thymoma: is hyperthermic intrathoracic chemotherapy worthwhile?
    Aprile, Vittorio
    Bacchin, Diana
    Korasidis, Stylianos
    Nesti, Agnese
    Marrama, Elena
    Ricciardi, Roberta
    Petrini, Iacopo
    Ambrogi, Marcello Carlo
    Paladini, Piero
    Lucchi, Marco
    [J]. INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY, 2020, 30 (05) : 765 - 772
  • [3] The role of intracavitary therapies in the treatment of malignant pleural mesothelioma
    Bertoglio, Pietro
    Aprile, Vittorio
    Ambrogi, Marcello Carlo
    Mussi, Alfredo
    Lucchi, Marco
    [J]. JOURNAL OF THORACIC DISEASE, 2018, 10 : S293 - S297
  • [4] CAVALIER.R, 1967, CANCER-AM CANCER SOC, V20, P1351, DOI 10.1002/1097-0142(196709)20:9<1351::AID-CNCR2820200902>3.0.CO
  • [5] 2-#
  • [6] Prognostic factors after treatment for iterative thymoma recurrences: A multicentric experience
    Chiappetta, Marco
    Zanfrini, Edoardo
    Giraldi, Luca
    Mastromarino, Maria Giovanna
    Petracca-Ciavarella, Leonardo
    Nachira, Dania
    Congedo, Maria Teresa
    Aprile, Vittorio
    Ambrogi, Marcello Carlo
    Lucchi, Marco
    Filosso, Pier Luigi
    Ruffini, Enrico
    Guerrera, Francesco
    Mule, Antonino
    Ali, Greta
    Molinaro, Luca
    Lococo, Filippo
    Meacci, Elisa
    Margaritora, Stefano
    [J]. LUNG CANCER, 2019, 138 : 27 - 34
  • [7] The role of surgery in the management of thymoma: A systematic review
    Davenport, Eric
    Malthaner, Richard A.
    [J]. ANNALS OF THORACIC SURGERY, 2008, 86 (02) : 673 - 684
  • [8] Cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy in patients with malignant pleural mesothelioma or pleural metastases of thymoma
    de Bree, E
    van Ruth, S
    Baas, P
    Rutgers, EJT
    van Zandwijk, N
    Witkamp, AJ
    Zoetmulder, FAN
    [J]. CHEST, 2002, 121 (02) : 480 - 487
  • [9] Thymoma: current diagnosis and treatment
    Detterbeck, Frank C.
    Zeeshan, Ahmad
    [J]. CHINESE MEDICAL JOURNAL, 2013, 126 (11) : 2186 - 2191
  • [10] Thymoma A Focus on Current Therapeutic Management
    Girard, Nicolas
    Mornex, Francoise
    Van Houtte, Paul
    Cordier, Jean-Francois
    van Schil, Paul
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (01) : 119 - 126